Hormonal
Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy improve glucose metabolism and induce weight loss primarily through accelerated nutrient transit to the distal small intestine, which triggers exaggerated secretion of L-cell hormones (GLP-1, PYY) that enhance insulin secretion and suppress appetite.
Metabolic surgeries like RYGB and sleeve gastrectomy work by rerouting the gut to stimulate GLP-1 and PYY hormones, which naturally suppress appetite and improve insulin sensitivity. This hormonal shift is a key driver of sustained weight loss and diabetes remission, offering benefits beyond simple calorie restriction.
Importantly, gut hormone secretion is altered after RYGB and sleeve gastrectomy due to accelerated transit of nutrients to distal parts of the small intestine, leading to excessive release of L-cell peptide hormones [e.g. glucagon-like peptide-1 (GLP-1), peptide YY].
Why this rating
Based on a review of multiple human studies, including pharmacological blockade experiments (Exendin 9-39) confirming causality.
Source
Updates in weight loss surgery and gastrointestinal peptides
Maria S. Svane et al. · Current Opinion in Endocrinology Diabetes and Obesity · 2015
DOI 10.1097/med.0000000000000131
More from this paper
- Exaggerated secretion of GLP-1 following RYGB and sleeve gastrectomy is causally responsible for improved postprandial beta-cell function and glucose tolerance, as demonstrated by the reversal of these benefits when GLP-1 receptors are blocked.Strong
- The early improvement in hepatic insulin sensitivity after RYGB is primarily driven by postoperative caloric restriction and reduced liver fat, rather than surgery-specific anatomical effects.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →